Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;1(6):452-472.
doi: 10.37349/etat.2020.00029. Epub 2020 Dec 28.

An overview of immune checkpoint inhibitors in breast cancer

Federica Miglietta  1   2 , Maria Silvia Cona  3 , Maria Vittoria Dieci  1   2 , Valentina Guarneri  1   2 , Nicla La Verde  3
Affiliations
Review

An overview of immune checkpoint inhibitors in breast cancer

Federica Miglietta et al. Explor Target Antitumor Ther. 2020.

Abstract

Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.

Keywords: Early breast cancer; immune checkpoint inhibitors; immunotherapy; metastatic breast cancer.

PubMed Disclaimer

Conflict of interest statement

VG reports grants (Institution) and personal fees from Roche, personal fees from Novartis, and personal fees from Eli Lilly, outside the submitted work. MVD reports personal fees from Genomic Health, EliLilly, and Celgene, outside the submitted work. NLV reports grants from EISAI; speaker bureau, travel expences for conference from ROCHE, GENTILI; advisory role from NOVARTIS and CELGENE; advisor role, travel expences for conference from PFIZER; advisory board from MSD, outside the submitted work. FM and MSC declare that they have no conflicts of interest.

References

    1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. Erratum in: Nature. 2013;502:258. Imielinsk, Marcin [corrected to Imielinski, Marcin]. 10.1038/nature12477 - DOI - PMC - PubMed
    1. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2:1354–60. 10.1001/jamaoncol.2016.1061 - DOI - PubMed
    1. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13. Erratum in: J Clin Oncol. 2010;28:708. 10.1200/JCO.2009.23.7370 - DOI - PubMed
    1. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7. 10.1200/JCO.2011.41.0902 - DOI - PubMed
    1. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41. 10.1038/nrclinonc.2015.215 - DOI - PubMed

LinkOut - more resources